Notably, EPS364 significantly inhibited cancer cell growth and adhesion via targeting the FGF19-FGFR4 signaling pathway, indicating that EPS364 could be developed as an anti-liver cancer drug candidate. This evidence concerns the gene FGF19 and liver cancer.